CASI Pharmaceuticals (CASIF) Profit After Tax (2022 - 2025)

CASI Pharmaceuticals has reported Profit After Tax for 4 years, with the latest figure at -$83.1 million in Q4 2025.

• For the quarter ending Q4 2025, Profit After Tax fell 478.1% year-over-year to -$83.1 million; the trailing twelve-month figure through Dec 2025 stood at -$96.6 million (down 146.02% YoY), and the FY2025 full-year result was -$48.1 million, down 22.42% from the prior year.
• Profit After Tax for Q4 2025 stood at -$83.1 million, down from -$10.9 million in the prior quarter.
• The five-year high for Profit After Tax was $61.2 million in Q4 2022, with the low at -$83.1 million in Q4 2025.
• Historically, Profit After Tax has averaged -$7.7 million across 4 years, with a median of -$7.9 million in 2022.
• The largest YoY upside for Profit After Tax was 212.83% in 2025 against a maximum downside of 478.1% in 2025.
• CASI Pharmaceuticals' Profit After Tax stood at $61.2 million in 2022, then plunged by 110.78% to -$6.6 million in 2023, then tumbled by 117.96% to -$14.4 million in 2024, then sank by 478.1% to -$83.1 million in 2025.
• The last three Profit After Tax figures came in at -$83.1 million (Q4 2025), -$10.9 million (Q3 2025), and -$13.4 million (Q2 2025), per Business Quant data.